BRAF and thyroid gland papillary carcinoma: For instance, discovery of the oncogenic BRAF V600E mutation in high frequency (50–70%) in papillary thyroid cancers and its associated implication for susceptibility to BRAF targeted therapies have dramatically shifted the landscape of papillary thyroid cancer treatment (7).